课题基金 / 基金详情

BRL49653 IN PATIENTS WITH HEPATIC IMPAIRMENT

BRL49653 IN PATIENTS WITH HEPATIC IMPAIRMENT
BRL49653 用于肝损伤患者
批准号：
6281023
负责人：
STEVEN SCHENKER
金额：
$1.49万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281023
关键词：
clinical research drug screening /evaluation human subject hyperglycemic agent liver disorder pharmacokinetics

项目摘要

项目成果

STEVEN SCHENKER的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is an open label, parallel group, single dose study to determine the safety and tolerability of a single oral dose of BRL 49653C (a new anti- hyperglycemic agent) in patients with hepatic impairment and in healthy volunteers. The pharmacokinetics of the metabolites will also be determined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS